The identification of the MHC II transactivator CIITA as a YAP/TAZ-TEAD-TP63 target gene was notable, particularly given the reported low expression of MHC class II genes in progressive bronchial PML [8, 9] and the similar decreases observed in CIITA and MHC class II gene expression with poor immunotherapy responses in melanoma patients and in a rat model of breast cancer [91, 92] and with promoting intestinal tumorigenesis [93]. This evidence concerns the gene YAP1 and melanoma.